DC
Decheng Capital Portfolio holdings
AUM
$396M
This Quarter Return
-23.9%
1 Year Return
-5.21%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$356M
AUM Growth
+$356M
(-24%)
Cap. Flow
+$9.61M
Cap. Flow
% of AUM
2.7%
Top 10 Holdings %
Top 10 Hldgs %
86.5%
Holding
29
New
1
Increased
2
Reduced
8
Closed
2
Top Buys
| 1 |
AARD
Aardvark Therapeutics, Inc. Common Stock
AARD
|
$29.4M |
| 2 |
Aclaris Therapeutics
ACRS
|
$2.72M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$335K |
Top Sells
| 1 |
Illumina
ILMN
|
$6.59M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
$5.64M |
| 3 |
Arcellx
ACLX
|
$2.26M |
| 4 |
Krystal Biotech
KRYS
|
$2.12M |
| 5 |
BioNTech
BNTX
|
$1.82M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.04B
| $156M | 43.77% | 6,371,669 | – | – |
|
2
Nuvation Bio
NUVB
$1.02B
| $45.7M | 12.81% | 25,954,439 | – | – |
|
|
AARD
3
Aardvark Therapeutics, Inc. Common Stock
AARD
$180M
| $29.4M | 8.25% | +3,917,299 | New | +$29.4M |
|
|
UPB
4
Upstream Bio, Inc. Common Stock
UPB
$923M
| $20.1M | 5.64% | 3,285,293 | – | – |
|
5
NewAmsterdam Pharma
NAMS
$2.71B
| $15.8M | 4.42% | 770,000 | – | – |
|
|
6
Krystal Biotech
KRYS
$4.27B
| $11.7M | 3.29% | 65,000 -11,772 | -15% | -$2.12M |
|
7
Revolution Medicines
RVMD
$7.1B
| $7.99M | 2.24% | 226,000 | – | – |
|
8
Merus
MRUS
$4.98B
| $7.96M | 2.23% | 189,098 | – | – |
|
9
BeyondSpring
BYSI
$69.4M
| $6.97M | 1.96% | 4,882,651 | – | – |
|
10
MoonLake Immunotherapeutics
MLTX
$3.54B
| $6.7M | 1.88% | 171,600 | – | – |
|
11
Lyell Immunopharma
LYEL
$213M
| $6.41M | 1.8% | 11,909,341 | – | – |
|
12
Arcus Biosciences
RCUS
$1.13B
| $6.35M | 1.78% | 808,789 | – | – |
|
|
13
Aclaris Therapeutics
ACRS
$209M
| $6.18M | 1.73% | 4,041,736 +1,775,069 | +78% | +$2.72M |
|
|
14
Crinetics Pharmaceuticals
CRNX
$2.92B
| $5.97M | 1.67% | 177,958 +10,000 | +6% | +$335K |
|
15
Cytokinetics
CYTK
$4.23B
| $4.02M | 1.13% | 100,000 | – | – |
|
16
Legend Biotech
LEGN
$6.41B
| $3.39M | 0.95% | 100,000 -53,558 | -35% | -$1.82M |
|
|
17
Arcellx
ACLX
$3.85B
| $3.28M | 0.92% | 50,000 -34,377 | -41% | -$2.26M |
|
18
Zentalis Pharmaceuticals
ZNTL
$122M
| $3.21M | 0.9% | 2,019,762 -318,333 | -14% | -$506K |
|
19
Aura Biosciences
AURA
$389M
| $3.02M | 0.85% | 515,555 | – | – |
|
|
20
BioNTech
BNTX
$24B
| $1.82M | 0.51% | 20,000 -20,000 | -50% | -$1.82M |
|
21
Equillium
EQ
$62.2M
| $1.74M | 0.49% | 4,447,308 | – | – |
|
22
4D Molecular Therapeutics
FDMT
$288M
| $1.08M | 0.3% | 335,515 -64,485 | -16% | -$208K |
|
|
23
Illumina
ILMN
$15.8B
| $932K | 0.26% | 11,749 -83,018 | -88% | -$6.59M |
|
24
Pyxis Oncology
PYXS
$79.4M
| $320K | 0.09% | 326,810 | – | – |
|
|
GRAL
25
GRAIL, Inc. Common Stock
GRAL
$1.18B
| $247K | 0.07% | 9,684 | – | – |
|